摘要
Eph受体是酪氨酸激酶受体(RTK)中最大的亚家族。Eph受体及其肝配蛋白配体,在细胞间信息介导及其发展过程中发挥着核心作用,也在正常成人的生理保养中占据重要角色。因此,它们发生异常,可以促使人类各种疾病发生。目前,由于Eph受体和其配体的结构已被很好的特征化,并有广泛的最新技术以发展方式来操纵他们,以达到较好的治疗效果。虽然一些试验已进展到临床试验阶段,但到目前为止,显而易见,Eph受体是治疗药物的有效靶点。本文首先研究和总结Eph受体三维结构,其次我们将概述以Ephs为靶点的小分子抑制剂和激活剂的使用情况,同时我们将特别侧重于单克隆抗体或抑制或激活Eph/ephrin信号抗体领域的最新发展。
关键词: 三维结构,药物靶点,Eph受体,单克隆抗体,酪氨酸激酶受体,单链抗体,小分子抑制剂。
图形摘要
Current Drug Targets
Title:Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Volume: 16 Issue: 10
Author(s): Urpo Lamminmaki, Dimitar Nikolov and Juha Himanen
Affiliation:
关键词: 三维结构,药物靶点,Eph受体,单克隆抗体,酪氨酸激酶受体,单链抗体,小分子抑制剂。
摘要: The Eph receptors are the largest sub-family of Receptor Tyrosine Kinases (RTK). They, together with their ephrin ligands, play central roles in cell-cell communication during development, and also in the maintenance of a normal adult physiology. Their malfunction, therefore, can contribute to various human diseases. Since the structures of the Eph receptors and ephrins are by now well characterized, there has been extensive recent work to develop ways to manipulate their action in order to achieve therapeutic benefits. Although few reagents have progressed to clinical trials thus far, it is evident that the Eph receptors are valid targets for therapeutic drugs. In this review we first summarize studies on the three-dimensional structures of Eph receptors. We then give an overview on small molecule inhibitors and activators using Ephs as targets. We put a special focus on the latest developments in the field of monoclonal antibodies and antibody fragments for inhibiting or activating the Eph/ephrin signaling.
Export Options
About this article
Cite this article as:
Urpo Lamminmaki, Dimitar Nikolov and Juha Himanen , Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond, Current Drug Targets 2015; 16 (10) . https://dx.doi.org/10.2174/1389450116666150531154619
DOI https://dx.doi.org/10.2174/1389450116666150531154619 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Development of Drugs Interfering with Apoptosis (Executive Guest Editor: Sebastiano Cavallaro)]
Current Pharmaceutical Design The Use of SIFT-MS to Investigate Headspace Aldehydes as Markers of Lipid Peroxidation
Current Analytical Chemistry Statins, Mevalonate Pathway and its Intermediate Products in Placental Development and Preeclampsia
Current Molecular Pharmacology In vivo Radiosensitization of Human Glioma U87 Cells Induced by Upregulated Expression of DUSP-2 after Treatment with Curcumin
Current Signal Transduction Therapy Cyclic ADP-ribose (cADPR) and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP): Novel Regulators of Ca 2+-Signaling and Cell Function
Current Molecular Medicine Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer
Current Medicinal Chemistry Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents
Current Medicinal Chemistry Retinal Ganglion Cell Gene Therapy and Visual System Repair
Current Gene Therapy Integrin-Mediated Drug Resistance
Current Signal Transduction Therapy Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: The Kynurenine and Melatonergic Pathways in Psychiatric and CNS Disorders)
Current Pharmaceutical Design Viewpoints on Medical Image Processing: From Science to Application
Current Medical Imaging Dual Targeting of Autophagy and NF-κB Pathway by PPARγ Contributes to the Inhibitory Effect of Demethoxycurcumin on NLRP3 Inflammasome Priming
Current Molecular Pharmacology Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Phenanthrene Dimers: Promising Source of Biologically Active Molecules
Current Topics in Medicinal Chemistry Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry